Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2299-5684
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance ; volume:72 ; number:4 ; day:14 ; month:7 ; year:2020 ; pages:799-813 ; date:8.2020
Pharmacological reports ; 72, Heft 4 (14.7.2020), 799-813, 8.2020
- Urheber
-
Maity, Swastika
Pai, K. Sreedhara Ranganath
Nayak, Yogendra
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s43440-020-00131-0
- URN
-
urn:nbn:de:101:1-2020092311441318130332
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Maity, Swastika
- Pai, K. Sreedhara Ranganath
- Nayak, Yogendra
- SpringerLink (Online service)
Ähnliche Objekte (12)
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC